Navigation Links
PAREXEL International Expands Relationship with Synchron Research in India and Divests Bioanalytical Laboratory in France
Date:3/27/2008

BOSTON, March 27 /PRNewswire-FirstCall/ -- PAREXEL International Corporation ("PAREXEL") (Nasdaq: PRXL) today announced that it has expanded its minority interest ownership in the clinical pharmacology business of Synchron Research in Ahmedabad, India. The Company also announced the sale of a bioanalytical laboratory in Poitiers, France to a subsidiary of Synchron, SYNEXEL Research International.

Under the terms of the new agreement, PAREXEL's ownership interest in the Ahmedabad Phase I business has increased from 19.5% to 31.0% on a fully diluted basis, at a cost of approximately $5.0 million dollars. In a separate transaction, PAREXEL sold the Poitiers business to Synchron's SYNEXEL Research International for approximately $6.7 million dollars. Staff of the bioanalytical lab in Poitiers, France will join Synchron's bioanalytical business unit.

"Over the past several years, PAREXEL has developed a strong global clinical pharmacology capability, through both organic growth and acquisitions. As a result, we are an industry leader in expertise-based Phase I studies," said Josef H. von Rickenbach, Chairman and Chief Executive Officer, PAREXEL International. "PAREXEL's increased investment in Synchron's clinical pharmacology business demonstrates our commitment to helping clients select the most promising compounds earlier by providing complex, multi-site Phase I and Proof of Concept studies. We have a long-term commitment to conducting high quality clinical studies in India, and continue to strengthen our presence, both in India and globally, to help clients bring important new biopharmaceutical products to market."

In 2004, PAREXEL entered into an exclusive strategic collaboration with Synchron, a privately-held contrac
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PAREXEL Announces Date of Third Quarter Fiscal Year 2008 Earnings Release and Conference Call
2. PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team
3. PAREXEL International to Present at Lehman Brothers 11th Annual Global Healthcare Conference
4. PAREXEL International to Present at Raymond James 29th Annual Institutional Investors Conference
5. PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting
6. PAREXEL International Announces 2-For-1 Stock Split
7. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
8. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
9. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
10. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
11. PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... August 22, 2014 Nerium International, ... is in the spotlight again. Nerium will showcase ... its NeriumFirmTM Body Contouring Cream to Hollywood’s elite ... Creations during the 66th Primetime Emmy® Awards. , ... extract, third-party clinical trials show that NeriumAD night ...
(Date:8/21/2014)... 2014 DNA vaccine pioneer Immunomic ... development of JRC-LAMP-vax, an innovative and safe potential treatment ... studies began this month in Hawaii, moving the world ... The Japanese red cedar releases pollen that causes devastating ... Cedar pollen wreaks similar havoc in Colorado, New Mexico ...
(Date:8/21/2014)... , August 21, 2014 ... http://www.researchandmarkets.com/research/3zh3q8/global_hormone ) has announced the addition of ...  report to their offering.       ... as hormone therapy, is a means of ... produced by the body. This type of ...
(Date:8/21/2014)... , Aug. 21, 2014  Decision Resources Group ... Brazil and Mexico ... of several newly approved agents, the anticipated label ... and the launch of emerging biologics will substantially ... particular, the emerging IL-5 inhibitors will introduce a ...
Breaking Biology Technology:Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3
... neuromodulation products designed to accelerate recovery from central nervous system ... of inpatient rehabilitative healthcare services, will expand the availability of ... Foot Drop System to 88 rehabilitation hospitals nationwide. ... ...
... ON ALS CLINICALS AND DRUG DEVELOPMENT, ROCKVILLE, ... (Amex: CUR ) announced that Dr. Thomas ... President, Research. He will be,working with Dr. Karl ... the company,s upcoming clinical trial for ALS,(Amytrophic Lateral ...
... Proceeds to Advance Clinical Development Of Lead Drug ... Cytochroma today announced the,closing of a CDN $45 ... by a,new investor, Mitsubishi Tanabe Pharma Corporation ("MTPC"), ... Vengrowth Advanced Life,Sciences Fund Inc., Caisse de Depot ...
Cached Biology Technology: Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide 2 Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide 3Neuralstem Fills Key Product Development Position 2Cytochroma Closes $45 Million Series C Financing 2Cytochroma Closes $45 Million Series C Financing 3
(Date:8/21/2014)... dandruff, eczema and other itchy, flaky maladies in humans ... Hawaiian coral reefs and the extreme environments of arctic ... the scientific journal PLOS Pathogens considers the ... genus Malassezia in light of new insights ... world. , University of Hawai,i at Mānoa scientist Anthony ...
(Date:8/21/2014)... improving the food intake, health and quality of life ... three projects at the University of Waterloo receiving close ... of Health Research (CIHR). , Professor Heather Keller, ... and a Schlegel research chair in nutrition and aging, ... many Canadians living in long-term care homes are poorly ...
(Date:8/21/2014)... a finding that has implications for life in other ... the solar system, LSU Associate Professor of Biological Sciences ... Science Foundation, or NSF, this week published a paper ... that lies 800 meters (2600 feet) beneath the surface ... ecosystems.", Given that more than 400 subglacial lakes and ...
Breaking Biology News(10 mins):From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2Grants will fund landmark aging research at Waterloo 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 3800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 4
... train passenger, a molecule called oskar RNA carries a ... scientists at the European Molecular Biology Laboratory (EMBL) in ... molecule, moving in the right direction isn,t enough: speed ... in Nature Structural & Molecular Biology , also ...
... A paper published online today in Nature ... to replace faulty immune system cells in models of ... the childhood disorder, including abnormal breathing and movement, and ... the function of microglia deficient in methyl-CpG binding protein ...
... no surprise that giant and colossal squid are big, but ... comes to size, with diameters measuring two or three times ... March 15 in Current Biology , a Cell Press ... Giant squids, 10-inch eyes allow them to see very large ...
Cached Biology News:Need for speed 2Bone marrow transplant arrests symptoms in model of Rett syndrome 2Bone marrow transplant arrests symptoms in model of Rett syndrome 3Giant squids' giant eyes: The better to see hungry whales with 2
Integrins Sampler Kit 10g each...
Protein Tyrosine Phosphatase Sampler Kit 10g each...
... reagent for Virus isolation ... unique water insoluble Elastomeric ... and chaotropes; Engineered to ... viruses while preserving infectivity; ...
Caveolin Sampler Kit 10g each...
Biology Products: